Galectin Therapeutics Inc

Market Cap

$172M

Healthcare·Biotechnology·🇺🇸 United States·NASDAQ

Healthcare·Biotechnology·🇺🇸·NASDAQ

Stock Price

$2.33-$1.72 (-42.47%)

Jun 5, 2026

52W High $6.5152W Low $1.32

Company Details

Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in drug development to create new therapies for fibrotic disease and cancer. The company's lead product candidate is belapectin (GR-MD-02), a galectin-3 inhibit...

CEO

—

IPO Date

Sep 9, 2002

Website

galectintherapeutics.com

Key Metrics TTM

Revenue

-100.0% YoY

Net Income

-$26M

EPS (Diluted)

Free Cash Flow

-$20M

Revenue / Share

$0.00

Gross Margin

Operating Margin

Net Margin

FCF Margin

P/S

P/E

Earnings Reports

Q1 2026

May 15, 2026

FY 2025

Mar 31, 2026

Q4 2025

Mar 31, 2026

$0-100.0%

Q3 2025

Nov 14, 2025

Q2 2025

Aug 14, 2025

Revenue & Profitability

Valuation

Operating Cash Flow

CapEx Spend

OpEx vs Revenue Growth (YoY)

Stock-Based Compensation

OpEx Breakdown

War Chest

Shares Outstanding

Revenue Per Employee

Revenue / Employee